Mounjaro vs Ozempic in Calgary: A New Benchmark for Weight Loss
If you have been researching medical weight loss in Calgary and came across Mounjaro or tirzepatide, you are looking at what is currently the most effective weight loss medication approved in Canada. In head-to-head data, tirzepatide produces significantly greater weight loss than semaglutide — and Calgary patients who do not respond fully to Ozempic or Wegovy are increasingly asking about it.
"Tirzepatide works on two hunger-regulating pathways simultaneously where semaglutide works on one. That dual mechanism is why the clinical results are so much stronger."
What Is Tirzepatide and How Is It Different from Semaglutide?
Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist — it activates the glucagon-like peptide-1 receptor. Tirzepatide (Mounjaro) is a dual GLP-1/GIP receptor agonist — it activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. Activating both receptors produces an additive effect on hunger suppression, caloric intake reduction, and metabolic rate.
SURMOUNT Trial Results: The Clinical Data Calgary Patients Should Know
- 5 mg dose: Average 15 percent body weight loss over 72 weeks
- 10 mg dose: Average 19.5 percent body weight loss over 72 weeks
- 15 mg dose: Average 20.9 percent body weight loss over 72 weeks
- Placebo: 3.1 percent body weight loss
- One-third of participants at the highest dose lost 25 percent or more of body weight
For context: semaglutide (Wegovy) at 2.4 mg produces average weight loss of 14.9 percent over 68 weeks. Tirzepatide at 15 mg produces 20.9 percent over a similar timeframe — roughly 40 percent more weight loss on average.
Who Should Consider Tirzepatide Instead of Semaglutide?
- Patients who did not respond sufficiently to a full course of Ozempic or Wegovy
- Patients with Type 2 diabetes who need both superior blood sugar control and weight management
- Patients with significant obesity (BMI over 40) where more aggressive outcomes are clinically indicated
- Patients who tolerated semaglutide well and want to escalate to a more effective treatment
Mounjaro Cost in Calgary
Tirzepatide (Mounjaro) monthly out-of-pocket cost in Calgary ranges from approximately $350 to $500 per month depending on dose. Coverage through private insurance is growing as more plans recognize tirzepatide for weight management indications, though it lags slightly behind semaglutide coverage in terms of plan adoption.
Frequently Asked Questions
Is Mounjaro better than Ozempic for weight loss in Calgary?
In clinical trials, tirzepatide (Mounjaro) has consistently outperformed semaglutide (Ozempic/Wegovy) in average percentage of body weight lost. For most patients focused primarily on weight loss, tirzepatide is the stronger medication. However, semaglutide has more long-term cardiovascular outcome data and may be preferred for patients with established heart disease.
Can I switch from Ozempic to Mounjaro in Calgary?
Yes. Patients who have plateaued on semaglutide or want to pursue stronger outcomes can transition to tirzepatide under physician supervision. There is a transition protocol for switching between the two medications that your Calgary MediSpa physician will manage.
Is Zepbound available in Calgary?
Zepbound is the brand name for tirzepatide specifically approved for weight management in the US. In Canada, the approved brand is Mounjaro, which contains the same active ingredient. As of mid-2026, Zepbound as a distinct brand has not received separate Health Canada approval — Mounjaro is the available and appropriate Canadian equivalent.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before undergoing any medical procedure.